Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

A multicenter case registry study on medication-related osteonecrosis of the jaw in patients with advanced cancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Drugs and diseases: Summary and consensus statements of group 1. The 5th EAO Consensus Conference 2018

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The effect of antiresorptive drugs on implant therapy: Systematic review and meta-analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Morten Schiodt
  • Saroj Vadhan-Raj
  • Mark S Chambers
  • Ourania Nicolatou-Galitis
  • Constantinus Politis
  • Ruxandra Coropciuc
  • Stefano Fedele
  • Danielle Jandial
  • Jeffrey Zhang
  • Haijun Ma
  • Deborah P Saunders
Vis graf over relationer

PURPOSE: This observational case registry study was designed to describe the natural history of cancer patients with medication-related osteonecrosis of the jaw (ONJ) and evaluate the ONJ resolution rate.

METHODS: Adults with a diagnosis of cancer and with a new diagnosis of ONJ were enrolled and evaluated by a dental specialist at baseline and every 3 months for 2 years and then every 6 months for 3 years until death, consent withdrawal, or loss to follow-up. The primary endpoint was the rate and time course of ONJ resolution. Secondary endpoints included frequency of incident ONJ risk factors, ONJ treatment patterns, and treatment patterns of antiresorptive agents for subsequent ONJ.

RESULTS: Overall, 327 patients were enrolled; 207 (63%) were continuing on study at data cutoff. Up to 69% of evaluable patients with ONJ had resolution or improvement during the study. ONJ resolution (AAOMS ONJ staging criteria) was observed in 114 patients (35%); median (interquartile range) time from ONJ onset to resolution was 7.3 (4.5-11.4) months. Most patients (97%) had received antiresorptive medication before ONJ development, 9 patients (3%) had not; 68% had received zoledronic acid, 38% had received denosumab, and 10% had received pamidronate (56% had received bisphosphonates only, 18% had received denosumab only, and 21% had exposure to both).

CONCLUSIONS: These results are consistent with those observed in clinical trials evaluating skeletal-related events in patients with advanced malignancy involving bone. Longer follow-up will provide further information on ONJ recurrence and resolution rates between medically and surgically managed patients.

OriginalsprogEngelsk
TidsskriftSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Vol/bind26
Udgave nummer6
Sider (fra-til)1905-1915
Antal sider11
ISSN0941-4355
DOI
StatusUdgivet - jun. 2018

ID: 56437778